BCM
NBIX icon

Brookstone Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Brookstone Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$789K Sell
4,681
-369
-7% -$54.7K 0.01% 785
2026
Q1 		$665K Buy
5,050
+949
+23% +$126K 0.01% 777
2025
Q4 		$582K Sell
4,101
-252
-6% -$36.5K 0.01% 808
2025
Q3 		$611K Buy
+4,353
New +$590K 0.01% 758

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Brookstone Capital Management's NBIX Position: Q2 2026 in Review

Brookstone Capital Management reduced its Neurocrine Biosciences (NBIX) stake by 7.3% in Q2 2026, selling an estimated $54.7K and leaving 4,681 shares worth $789K. The position accounts for 0.01% of the portfolio, ranked #785.

Brookstone Capital Management first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Brookstone Capital Management held 4,681 shares of Neurocrine Biosciences worth $789K as of Q2 2026.
  • Brookstone Capital Management sold 369 Neurocrine Biosciences shares in Q2 2026, an estimated $54.7K.
  • Neurocrine Biosciences made up 0.01% of Brookstone Capital Management's portfolio in Q2 2026, its #785 holding.
  • Brookstone Capital Management first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Brookstone Capital Management's 13F filing for Q2 2026, filed 15 Jul 2026.